A separate research study revealed that individuals on a 15mg maintenance dosage for a period of 72 weeks saw a weight loss of up to 22.4% Polycystic Ovary Syndrome (PCOS) Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH Insulin Resistance Syndromes Potential Cognitive and Neuroprotective Applications Animal models suggest that incretin therapies may exhibit neuroprotective effects
Each disease has different symptoms, yet all share an overactive immune response
NNMT is an enzyme expressed in adipose tissue, the liver, and other tissues
Optional Lifestyle Support Well guide you with nutrition and habit tips that complement your treatment
Some notice improved energy and sleep within weeks
We are pleased to see the clinically meaningful weight loss in people treated with our oral GLP-1 therapy CT-996, which could eventually help patients address both chronic weight management and glycemic control indications, said Levi Garraway, MD, PhD, Roches CMO and head of global product development